Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Gliosarcoma × ficlatuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Gliosarcoma 1 Glioblastoma 1

Interventions

Magnetic Resonance Spectroscopy 3 Temozolomide 2 Carboplatin 2 pazopanib 1 gallium Ga 68 dotatate 1 ficlatuzumab 1 Triiodothyronine 1 TIC10 compound 1 Sunitinib 1 Radiotherapy 1 Radiation 1 Procarbazine 1 Nivolumab 1 Methimazole 1 Magnetic Resonance Imaging 1 Lomustine 1 Isotretinoin 1 Irinotecan 1 Gadolinium DTPA 1 Filgrastim 1 Carmustine 1 Biopsy 1 Axitinib 1 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01189513 2012-02-20

SCH-900105 in Recurrent Glioblastoma

M.D. Anderson Cancer Center

Phase 1 Withdrawn

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡